Stocks · News reference
enGene Holdings Q2 EPS $(0.43) Beats $(0.47) Estimate
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
EnGene Therapeutics Appoints Michael Heffernan Board Chairman, Effective Immediately, Succeeding Richard Glickman
enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzinga's analyst ratings page.
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday
Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey. See full list here.